What changed in this filing

/stocks — the workspaceLOADING

Item 2. Unregistered Sales of Equity Securities

2020-11-09 compared with 2005-07-19 · 17 added, 57 removed, 0 unchanged (100% of the section changed)

Sales of Equity Securities and Use of Proceeds

following table details purchases by UTMD of its own securities during 1Q

PURCHASES OF EQUITY SECURITIES

Number of Shares Purchased (1)

Price Paid per Share

Number of Shares Purchased as Part of Publicly Announced Plans or

Number (or Approximate Dollar Value) of Shares that May be Purchased

the Plans or Programs (1)

2005 UTMD repurchased the above shares pursuant to a continued open market

repurchase program initially announced in August 1992.

Since 1992 through 1Q

2005, the Company has repurchased 6.0 million shares at an average cost of

$10.70 per share including broker commissions and fees in open market

transactions.

In addition, the Company conducted tender offer transactions

which it purchased an additional 2.8 million shares at an average cost of $9.76

per share including fees and administrative costs.

In total, UTMD has

repurchased over 8.8 million of its shares at an average price of $10.40 per

share since 1992.

To complete the picture relating to current shares

outstanding, since 1992 the Company’s employees and directors have exercised and

purchased 1.4 million option shares at an average price of $6.24 per share.

options were awarded at the market value of the stock on the date of the

frequency of UTMD’s open market share repurchases depends on the availability of

sellers and the price of the stock.

The board of directors has not established

an expiration date or a maximum dollar or share limit for UTMD’s continuing and

long term pattern of open market share repurchases.

purpose of UTMD’s ongoing share repurchases is to maximize the value of the

Company for its continuing shareholders, and maximize its return on shareholder

equity by employing excess cash generated by effectively managing its business.

UTMD does not intend to repurchase shares that would result in terminating

Nasdaq National Market listing.

Submission of Matters to a Vote of Security Holders

2005 at the annual meeting, shareholders of the Company approved the following

matters submitted to them for consideration:

Bennett and Ernst G.

Hoyer as directors of the Company;

Certification

of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section

the Sarbanes-Oxley Act of 2002

Certification

of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted

pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification

of CEO pursuant to 18 U.S.C.

§1350, as Adopted Pursuant to Section 906 of

the Sarbanes-Oxley Act of 2002

Certification

of Principal Financial Officer pursuant to 18 U.S.C.

§1350, as Adopted

Pursuant to Section 906 of the Sarbanes-Oxley Act of

to the requirements of the Securities Exchanges Act of 1934, the registrant

duly caused this report to be signed on its behalf by the undersigned thereunto

duly authorized.

MEDICAL PRODUCTS, INC.

Unregistered Sales of Equity Securities and Use of Proceeds

During 9M 2020, UTMD purchased 87,000 of its shares in the open market for $6,977 including commissions and fees.

During 9M 2019 UTMD purchased 5,000 of its shares in the open market for $398 including commissions and fees.

Title of Document

Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of CEO pursuant to 18 U.S.C.

§1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Certification of Principal Financial Officer pursuant to 18 U.S.C.

§1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The following financial information from the Utah Medical Products, Inc.

quarterly report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline Extensible Business Reporting Language (iXBRL):

(i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Statements of Stockholders’ Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.

Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UTAH MEDICAL PRODUCTS, INC.

Principal Financial Officer

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q/A

Item 2. Unregistered Sales of Equity Securities